Drug profile · INN
fomivirsen sodium
VITRAVENE PRESERVATIVE FREE
fomivirsen sodium (VITRAVENE PRESERVATIVE FREE) is a major intermediate early region 2 mrna antisense inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — fomivirsen sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
fomivirsen sodium (VITRAVENE PRESERVATIVE FREE) is a major intermediate early region 2 mrna antisense inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Major intermediate early region 2 mRNA antisense inhibitor
Primary target: Major intermediate early region 2 mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fomivirsen sodium?
fomivirsen sodium (VITRAVENE PRESERVATIVE FREE) is a major intermediate early region 2 mrna antisense inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for fomivirsen sodium?
VITRAVENE PRESERVATIVE FREE is a marketed brand name for fomivirsen sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fomivirsen sodium?
fomivirsen sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.